Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Carisma Therapeutics Inc CARM

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the... see more

NDAQ:CARM - Post Discussion

Carisma Therapeutics Inc > sesn flying flamming turd
View:
Post by floatinketucky on Jan 24, 2022 6:48am

sesn flying flamming turd

To catch is risk of splatter and burn.  The market know for sure. Just look to the chart.
More pain cometh. 

This song is Break it to me gently. But it was not gentle at all. The market knew quick. Play with a dead cat and get scratched. 

Down down down.. The market know SESN is not the FDA Darlin. 

I'm as bearish as the chart and facts. 

As bearish as the FDA guidlines for them...
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities